Zacharon Pharmaceuticals, Inc.

5626 Oberlin Dr Ste 100
San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 14
Total Value of Awards $5.54MM
First Award Date 07/01/06
Most Recent Award Date 07/15/12

Key Personnel

Last Name Name Awards Contact
Glass Charles Alexander Glass 6
Crawford Brett E Crawford 11
Brown Jillian R Brown 1

14 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/15/12 - 03/31/13

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to develop a central nervous system penetrant (CNS) small molecule therapy for Metachromatic Leukodystrophy (MLD). We will accomplish this by developing a cellular model of MLD to screen compound libraries in order to identify small molecule screening hits suitab...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application are aimed at progressing an innovative approach to treating mucopolysaccharidoses (MPS) toward clinical trials. MPS is a family of lysosomal storage diseases caused by mutations in the enzymes that normally degrade glycosaminoglycans (GAGs). Bec...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): The goal of this proposal is to develop a biomarker capable of definitively diagnosing and monitoring response to therapy in patients with Mucopolysaccharidosis (MPS) I, II and VI. These diseases are rare genetic conditions each caused by unique deficiencies in the lysosomal enzymes required for the degradati...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 05/01/11 - 04/30/12

DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application are aimed at progressing an innovative approach to treating mucopolysaccharidoses (MPS) toward clinical trials. MPS is a family of lysosomal storage diseases caused by mutations in the enzymes that normally degrade glycosaminoglycans (GAGs). Bec...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/11 - 10/31/11

DESCRIPTION (provided by applicant): Project Summary Using a novel high-throughput screening approach, we have recently identified the first selective small molecule inhibitors of the biosynthesis of gangliosides. The proposed funding will enable important preclinical development activities required to advance these promising compounds as...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/09/10 - 06/30/11

DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblastoma, melanoma, and astrocytoma). Clinical studies have shown that these tumor types consistently produce an altered array of gangliosides that can...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 05/17/10 - 04/30/11

DESCRIPTION (provided by applicant): Project Summary The studies proposed in this application will test the feasibility of treating mucopolysaccharidosis (MPS) through a novel therapeutic approach called Substrate Optimization Therapy (SOT). MPS is a family of lysosomal storage diseases caused by mutations in the enzymes that normally deg...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/21/09 - 12/30/10

DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblastoma, melanoma, and astrocytoma). Clinical studies have shown that these tumor types consistently produce an altered array of gangliosides that can...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/21/09 - 12/30/10

DESCRIPTION (provided by applicant): The underlying hypothesis of this proposal is that inhibitors of ganglioside biosynthesis will prevent or slow the growth of neural crest-derived tumors (neuroblastoma, melanoma, and astrocytoma). Clinical studies have shown that these tumor types consistently produce an altered array of gangliosides that can...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/12/08 - 02/28/10

DESCRIPTION (provided by applicant): A large number of deaths from epithelial tumors of the breast, prostate, lung, ovary, liver, and kidney are caused by metastatic spread of the primary tumor. Unfortunately, there are currently no drugs on the market that directly target cancer cells in the process of spreading (metastasis). The tumor antigen,...

Load More